Does Rallies show Form 4 insider transactions for FTRE?

Yes. Rallies tracks FTRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FTRE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FTRE. It does not provide personalized investment advice.

FTRE (Fortrea Holdings Inc. Common Stock) Stock Analysis - Insider Trades

Fortrea Holdings Inc. Common Stock (FTRE) is a publicly traded Healthcare sector company. As of May 21, 2026, FTRE trades at $13.70 with a market cap of $1.29B and a P/E ratio of -1.25. FTRE moved -0.15% today. Year to date, FTRE is -17.57%; over the trailing twelve months it is +192.11%. Its 52-week range spans $3.97 to $25.28. Analyst consensus is buy with an average price target of $15.58. Rallies surfaces FTRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FTRE stock inside the company?

Recent FTRE insider activity includes Parks Robert sold 2.00K, Morais Mark A. sold 1.80K, Mcconnell Jill G. sold 1.80K, Parks Robert sold 963, and Parks Robert sold 964. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FTRE Key Metrics

Key financial metrics for FTRE
Metric	Value
Price	$13.70
Market Cap	$1.29B
P/E Ratio	-1.25
EPS	$-10.81
Dividend Yield	0.00%
52-Week High	$25.28
52-Week Low	$3.97
Volume	738.32K
Avg Volume	0
Revenue (TTM)	$2.72B
Net Income	$-986.20M
Gross Margin	0.00%

Recent FTRE Insider Trades

Parks Robert sold 2.00K (~$26.88K) on May 18, 2026.
Morais Mark A. sold 1.80K (~$16.63K) on Mar 16, 2026.
Mcconnell Jill G. sold 1.80K (~$16.63K) on Mar 16, 2026.
Parks Robert sold 963 (~$8.60K) on Mar 10, 2026.
Parks Robert sold 964 (~$8.88K) on Mar 10, 2026.

Latest FTRE News

Fortrea Reports $660.5M Q4 Revenue, Sets $2.55B–$2.65B 2026 Revenue Guidance — Feb 26, 2026
Fortrea Names Oren Cohen Chief Medical Officer, Scott Dove Heads Clinical Pharmacology — Feb 17, 2026
Fortrea’s 13.5 P/E and 0.30 PEG Secure A Value Grade Over Prothena — Feb 13, 2026

FTRE Analyst Consensus

10 analysts cover FTRE: 0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.58.

Common questions about FTRE

Who is trading FTRE stock inside the company?: Recent FTRE insider activity includes Parks Robert sold 2.00K, Morais Mark A. sold 1.80K, Mcconnell Jill G. sold 1.80K, Parks Robert sold 963, and Parks Robert sold 964. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FTRE?: Yes. Rallies tracks FTRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FTRE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FTRE. It does not provide personalized investment advice.